HUP0402018A3 - 5-amino-7h-pyrazolo[4,3-e][1,2,4]triazolo[1,5-c]pyrimidine derivatives, their use and pharmaceutical compositions containing them - Google Patents
5-amino-7h-pyrazolo[4,3-e][1,2,4]triazolo[1,5-c]pyrimidine derivatives, their use and pharmaceutical compositions containing themInfo
- Publication number
- HUP0402018A3 HUP0402018A3 HU0402018A HUP0402018A HUP0402018A3 HU P0402018 A3 HUP0402018 A3 HU P0402018A3 HU 0402018 A HU0402018 A HU 0402018A HU P0402018 A HUP0402018 A HU P0402018A HU P0402018 A3 HUP0402018 A3 HU P0402018A3
- Authority
- HU
- Hungary
- Prior art keywords
- triazolo
- pyrazolo
- amino
- pharmaceutical compositions
- compositions containing
- Prior art date
Links
- SDJIOAOHYNKNBG-UHFFFAOYSA-N 3,5,6,8,10,11-hexazatricyclo[7.3.0.02,6]dodeca-1(9),2,4,7,11-pentaen-7-amine Chemical class C12=NC=NN2C(N)=NC2=C1C=NN2 SDJIOAOHYNKNBG-UHFFFAOYSA-N 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/14—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Neurology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US33434201P | 2001-11-30 | 2001-11-30 | |
| PCT/US2002/037710 WO2003048165A1 (en) | 2001-11-30 | 2002-11-26 | ADENOSINE A2a RECEPTOR ANTAGONISTS |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| HUP0402018A2 HUP0402018A2 (hu) | 2005-02-28 |
| HUP0402018A3 true HUP0402018A3 (en) | 2008-06-30 |
Family
ID=23306779
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HU0402018A HUP0402018A3 (en) | 2001-11-30 | 2002-11-26 | 5-amino-7h-pyrazolo[4,3-e][1,2,4]triazolo[1,5-c]pyrimidine derivatives, their use and pharmaceutical compositions containing them |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US6916811B2 (enExample) |
| EP (1) | EP1448565B1 (enExample) |
| JP (2) | JP4284182B2 (enExample) |
| KR (1) | KR20050044593A (enExample) |
| CN (1) | CN1692116A (enExample) |
| AR (1) | AR037680A1 (enExample) |
| AT (1) | ATE453647T1 (enExample) |
| AU (1) | AU2002346503A1 (enExample) |
| CA (1) | CA2468649C (enExample) |
| DE (1) | DE60234951D1 (enExample) |
| ES (1) | ES2336435T3 (enExample) |
| HU (1) | HUP0402018A3 (enExample) |
| IL (1) | IL161716A0 (enExample) |
| MX (1) | MXPA04005209A (enExample) |
| PE (1) | PE20030665A1 (enExample) |
| TW (1) | TW200306837A (enExample) |
| WO (1) | WO2003048165A1 (enExample) |
| ZA (1) | ZA200404161B (enExample) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT1283839E (pt) * | 2000-05-26 | 2005-08-31 | Schering Corp | Antagonistas do receptor a2a da adenosina |
| US6964288B2 (en) * | 2001-07-06 | 2005-11-15 | Ksaria Corporation | Apparatus and method for automated preparation of an optical fiber |
| JP4545437B2 (ja) | 2001-10-15 | 2010-09-15 | シェーリング コーポレイション | アデノシンａ２ａ受容体アンタゴニストとしてのイミダゾ（４，３−ｅ）−１，２，４−トリアゾロ（１，５−ｃ）ピリミジン |
| MXPA04000908A (es) * | 2002-05-30 | 2004-03-26 | King Pharmaceuticals Res & Dev | Compuestos farmaceuticamente activos que tienen estructura de anillo de pirazolotriazolopirimidina triciclica y metodos de uso. |
| MXPA05006790A (es) | 2002-12-19 | 2005-09-08 | Schering Corp | Usos de antagonistas del receptor adenosina a2a. |
| US7816353B2 (en) * | 2003-10-24 | 2010-10-19 | Exelixis, Inc. | P70S6 kinase modulators and method of use |
| DK1678182T3 (da) * | 2003-10-28 | 2007-06-04 | Schering Corp | Fremgangsmåde til fremstilling af substituerede 5-amino-pyrazolo[4,3-E]-1,2,4-triazolo-[1,5-C]pyrimidiner |
| CA2550071A1 (en) * | 2003-12-19 | 2005-07-07 | Schering Corporation | Pharmaceutical compositions |
| JPWO2006132275A1 (ja) * | 2005-06-07 | 2009-01-08 | 協和醗酵工業株式会社 | 運動障害の予防および／または治療剤 |
| ES2273599B1 (es) | 2005-10-14 | 2008-06-01 | Universidad De Barcelona | Compuestos para el tratamiento de la fibrilacion auricular. |
| PE20080145A1 (es) | 2006-03-21 | 2008-02-11 | Janssen Pharmaceutica Nv | Tetrahidro-pirimidoazepinas como moduladores de trpv1 |
| US7691869B2 (en) | 2007-03-30 | 2010-04-06 | King Pharmaceuticals Research And Development, Inc. | Pyrrolotriazolopyrimidine derivatives, pharmaceutical compositions containing them and methods of treating conditions and diseases mediated by the adenosine A2A receptor activity |
| JP5562865B2 (ja) | 2007-12-17 | 2014-07-30 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | Ｔｒｐｖ１のイミダゾロ−、オキサゾロ−、及びチアゾロピリミジン・モジュレーター |
| US20100203165A1 (en) | 2008-08-01 | 2010-08-12 | Gerald Horn | Compositions and methods for treatment of disorders or conditions of the eye |
| US12246013B2 (en) | 2008-08-01 | 2025-03-11 | Eye Therapies Llc | Vasoconstriction compositions and methods of use |
| US20100028266A1 (en) | 2008-08-01 | 2010-02-04 | Alpha Synergy Development. Inc. | Composition and methods for treating allergic response |
| US8952011B2 (en) | 2008-08-01 | 2015-02-10 | Eye Therapies Llc | Compositions and methods for the treatment of nasal conditions |
| TW201036614A (en) | 2008-12-30 | 2010-10-16 | Arqule Inc | Substituted 1H-pyrazolo[3,4-d]pyrimidine-6-amine compounds |
| EP2414361A1 (en) | 2009-03-31 | 2012-02-08 | ArQule, Inc. | Substituted heterocyclic compounds |
| US8987270B2 (en) | 2009-07-27 | 2015-03-24 | Eye Therapies Llc | Formulations of selective alpha-2 agonists and methods of use thereof |
| CA2782872A1 (en) * | 2009-12-17 | 2011-06-23 | Alpha Synergy Development, Inc. | Compositions and methods for ophthalmic delivery of nasal decongestants |
| US8445526B2 (en) | 2011-02-03 | 2013-05-21 | Glaucoma & Nasal Therapies Llc | Compositions and methods for treatment of glaucoma |
| US8999938B2 (en) | 2013-06-21 | 2015-04-07 | Gnt Llc | Ophthalmic lipophilic drug delivery vehicle formulations |
| CN110742893B (zh) * | 2018-07-23 | 2024-04-05 | 百济神州(北京)生物科技有限公司 | A2a受体拮抗剂治疗癌症的方法 |
| US12414952B2 (en) | 2018-11-20 | 2025-09-16 | Merck Sharp & Dohme Llc | Substituted amino triazolopyrimidine and amino triazolopyrazine adenosine receptor antagonists, pharmaceutical compositions and their use |
| JP2022507734A (ja) | 2018-11-20 | 2022-01-18 | メルク・シャープ・アンド・ドーム・コーポレーション | 置換アミノトリアゾロピリミジン及びアミノトリアゾロピラジンアデノシン受容体アンタゴニスト、医薬組成物及びそれらの使用 |
| JP2022511778A (ja) | 2018-11-30 | 2022-02-01 | メルク・シャープ・アンド・ドーム・コーポレーション | アデノシン受容体拮抗薬としての７－、８－及び１０－置換されたアミノトリアゾロキナゾリン誘導体、医薬組成物及びそれらの使用 |
| AR117164A1 (es) | 2018-11-30 | 2021-07-14 | Merck Sharp & Dohme | Derivados de amino-triazoloquinazolina 9-sustituidos como antagonistas del receptor de adenosina, composiciones farmacéuticas y su uso para el tratamiento de diversos tipos de cáncer |
| DE102019116986A1 (de) | 2019-06-24 | 2020-12-24 | Helmholtz-Zentrum Dresden-Rossendorf E. V. | Deuterierte 7-(3-(4-(2-([18F]Fluor)ethoxy)phenyl)propyl)-2-(furan-2-yl)-7H-pyrazolo[4,3-e][1,2,4]triazolo[1,5-c]pyrimidin-5-amin-Derivate |
| WO2021011670A1 (en) * | 2019-07-17 | 2021-01-21 | Teon Therapeutics, Inc. | Adenosine a2a receptor antagonists and uses thereof |
| CN112608316B (zh) | 2019-07-30 | 2022-10-21 | 厦门宝太生物科技股份有限公司 | 一种吡唑并三嗪类腺苷受体拮抗剂 |
| CN112592354B (zh) | 2019-07-30 | 2022-05-27 | 厦门宝太生物科技股份有限公司 | 一种异噁唑并嘧啶类杂环化合物的制备方法 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT1264901B1 (it) | 1993-06-29 | 1996-10-17 | Schering Plough S P A | Analoghi eterociclici di 1,2,4-triazolo(15-c)pirimidine ad attivita' antagonista per il recettore a2 dell'adenosina |
| US5565460A (en) * | 1993-07-27 | 1996-10-15 | Kyowa Hakko Koygo Co., Ltd. | Therapeutic purine agents for parkinson's disease |
| IT1277392B1 (it) * | 1995-07-28 | 1997-11-10 | Schering Plough S P A | Analoghi eterociclici di 1,2,4-triazolo(1,5-c]pirimidine ad attivita' antagonista per il recettore a2a dell'adenosina |
| IT1291372B1 (it) | 1997-05-21 | 1999-01-07 | Schering Plough S P A | Uso di analoghi eterociclici di 1,2,4-triazolo (1,5-c) pirimidine per la preparazione di medicamenti utili per il trattamento delle malattie |
| US6921825B2 (en) * | 1998-09-16 | 2005-07-26 | King Pharmaceuticuals Research & Development, Inc. | Adenosine A3 receptor modulators |
| US6448253B1 (en) * | 1998-09-16 | 2002-09-10 | King Pharmaceuticals Research And Development, Inc. | Adenosine A3 receptor modulators |
| PT1283839E (pt) * | 2000-05-26 | 2005-08-31 | Schering Corp | Antagonistas do receptor a2a da adenosina |
| MXPA04000908A (es) * | 2002-05-30 | 2004-03-26 | King Pharmaceuticals Res & Dev | Compuestos farmaceuticamente activos que tienen estructura de anillo de pirazolotriazolopirimidina triciclica y metodos de uso. |
| EP1622912B1 (en) * | 2003-04-23 | 2009-05-27 | Schering Corporation | 2-alkynyl-and 2-alkenyl-pyrazolo- [4,3-e ] -1,2,4-triazolo- [1,5-c] -pyrimidine adenosine a2a receptor antagonists |
-
2002
- 2002-11-26 AU AU2002346503A patent/AU2002346503A1/en not_active Abandoned
- 2002-11-26 JP JP2003549355A patent/JP4284182B2/ja not_active Expired - Fee Related
- 2002-11-26 US US10/304,931 patent/US6916811B2/en not_active Expired - Lifetime
- 2002-11-26 WO PCT/US2002/037710 patent/WO2003048165A1/en not_active Ceased
- 2002-11-26 EP EP02784568A patent/EP1448565B1/en not_active Expired - Lifetime
- 2002-11-26 CN CNA02823782XA patent/CN1692116A/zh active Pending
- 2002-11-26 IL IL16171602A patent/IL161716A0/xx unknown
- 2002-11-26 ES ES02784568T patent/ES2336435T3/es not_active Expired - Lifetime
- 2002-11-26 HU HU0402018A patent/HUP0402018A3/hu unknown
- 2002-11-26 DE DE60234951T patent/DE60234951D1/de not_active Expired - Lifetime
- 2002-11-26 KR KR1020047007876A patent/KR20050044593A/ko not_active Withdrawn
- 2002-11-26 MX MXPA04005209A patent/MXPA04005209A/es active IP Right Grant
- 2002-11-26 CA CA002468649A patent/CA2468649C/en not_active Expired - Fee Related
- 2002-11-26 AT AT02784568T patent/ATE453647T1/de not_active IP Right Cessation
- 2002-11-27 AR ARP020104561A patent/AR037680A1/es unknown
- 2002-11-27 TW TW091134471A patent/TW200306837A/zh unknown
- 2002-11-27 PE PE2002001143A patent/PE20030665A1/es not_active Application Discontinuation
-
2004
- 2004-05-27 ZA ZA200404161A patent/ZA200404161B/en unknown
-
2008
- 2008-06-04 JP JP2008147306A patent/JP2008260776A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP1448565B1 (en) | 2009-12-30 |
| HK1063780A1 (en) | 2005-01-14 |
| ATE453647T1 (de) | 2010-01-15 |
| AR037680A1 (es) | 2004-12-01 |
| JP2008260776A (ja) | 2008-10-30 |
| DE60234951D1 (de) | 2010-02-11 |
| US6916811B2 (en) | 2005-07-12 |
| WO2003048165A1 (en) | 2003-06-12 |
| CA2468649A1 (en) | 2003-06-12 |
| JP4284182B2 (ja) | 2009-06-24 |
| HUP0402018A2 (hu) | 2005-02-28 |
| CN1692116A (zh) | 2005-11-02 |
| ES2336435T3 (es) | 2010-04-13 |
| ZA200404161B (en) | 2005-11-30 |
| TW200306837A (en) | 2003-12-01 |
| PE20030665A1 (es) | 2003-08-08 |
| US20030212059A1 (en) | 2003-11-13 |
| EP1448565A1 (en) | 2004-08-25 |
| KR20050044593A (ko) | 2005-05-12 |
| JP2005511699A (ja) | 2005-04-28 |
| IL161716A0 (en) | 2004-09-27 |
| CA2468649C (en) | 2009-03-10 |
| MXPA04005209A (es) | 2004-08-19 |
| AU2002346503A1 (en) | 2003-06-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HUP0401047A3 (en) | Triazolo[4,5-d]pyrimidine derivatives, their use as purinergic receptor antagonist and pharmaceutical compositions containing same | |
| HUP0500332A3 (en) | Substituted 2-pyrimidinyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one and 7-pyrimidinyl-2,3-dihydroimidazo[1,2-a]pyrimidin-5(1h)-one derivatives, their use and pharmaceutical compositions containing them | |
| HUP0400692A3 (en) | Substituted 7h-pyrrolo[2,3-d]pyrimidine derivatives, their use and pharmaceutical compositions containing them | |
| IL191960A (en) | History of imidazo [5,1– a] pyridine and pharmaceutical preparations containing them | |
| HUP0303350A3 (en) | Use of substituted imidazo[1,2-a]pyridine-, imidazo[1,2-a]pyrimidine and imidazo[1,2-a]pyrazine-3-yl-amine derivatives for producing nos-inhibiting pharmaceutical compositions | |
| HUP0400784A3 (en) | Bicyclic heterocondensated pyrrolcarboxamide derivatives, their use and pharmaceutical compositions containing them | |
| PL377239A1 (pl) | Nowe amino-podstawione pochodne dihydropirymido [4,5-d]-pirymidynonu, ich wytwarzanie i zastosowanie jako środków framaceutycznych | |
| HUP0200207A3 (en) | Substituted 2-aryl-3-(hetroaryl)-imidazo [1,2-a] pyrimidines, and related pharmaceutical compositions and methods for their preparation | |
| HUP0103921A3 (en) | [1,2,4]triazolo[1,5-c]pyrimidine derivatives and pharmaceutical compositions thereof | |
| HUP0301722A3 (en) | Pyrimidine derivatives, pharmaceutical compositions containing them and their use | |
| HUP0500328A3 (en) | Substituted 2-pyridinyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one and 7-pyridinyl-2,3-dihydroimidazo[1,2-a]pyrimidin-5(1h)-one derivatives, their use and pharmaceutical compositions containing them | |
| IL152889A0 (en) | Imidazopyridine and imidazopyrimidine derivatives and pharmaceutical compositions containing the same | |
| HUP0401718A3 (en) | Bicyclic oxopyridine and oxopyrimidine derivatives, their use and pharmaceutical compositions containing them | |
| HUP0402270A3 (en) | [1,2,4]triazolo[1,5-c]pyrimidin-5-yl-amines as adenosine a2a receptor antagonists and pharmaceutical compositions containing them | |
| HUP0203503A3 (en) | Pyrrolo[2,3-d]pirimidine compounds, pharmaceutical compositions containing them and their use | |
| HUP0301114A3 (en) | Pyrrolo[2,3-d]pyrimidine compounds as immunosuppressive agents and pharmaceutical compositions containing them | |
| HUP0401301A3 (en) | Pyrrolo pyrimidines, process for their preparation, their use and pharmaceutical compositions containing them | |
| HUP0105081A3 (en) | Triazolo[4,5-d]pyrimidine derivatives, process for their preparation, their use and pharmaceutical compositions containing them | |
| IL150734A0 (en) | Azaindole derivatives and pharmaceutical compositions containing the same | |
| PL373223A1 (en) | 7,8,9,10-tetrahydro-6h-azepino, 6,7,8,9-tetrahydro-pyrido and 2,3-dihydro-2h-pyrrolo[2,1-b]-quinazolinone derivatives | |
| IL128869A (en) | ARYSULFONYL-SUBSTITUTED-PYRAZOLO [1,5-a]-PYRIMIDINE AND PYRAZOLO [1,5-a] [1, 3, 5]-TRIAZINE DERIVATIVES, THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | |
| HUP0401777A3 (en) | 3h-[1,2,4]triazolo[5,1-i]purin-5-yl amines as adenosine a2a receptor antagonists and pharmaceutical compositions containing the compounds | |
| HUP0600239A3 (en) | 5-amino-pyrazolo[4,3-e][1,2,4]triazolo[1,5-c]pyrimidine derivatives, process for their preparation, their use as adenosine a2a receptor antagonists and pharmaceutical compositions containing them | |
| HUP0402336A3 (en) | Thieno[2,3-d]pyrimidine-2,4-dione derivatives, process for their preparation, their use in the modulation of autoimmune disease and pharmaceutical compositions containing them | |
| HUP0200324A3 (en) | 4-oxo-4,7-dihydro-thieno[2,3-b]pyridine-5-carboxamides as antiviral agents, pharmaceutical compositions containing them and useful intermediates in preparation the compounds and processes |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA9A | Lapse of provisional patent protection due to relinquishment or protection considered relinquished |